Moderna, Inc. (NASDAQ:MRNA) | Finanzwire

Basculer en Français

10592	Companies
224614	Keywords
153326	Articles
118806	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 07/02/2024 at 13:30, 1 year 11 months ago

Moderna Receives Project Award through BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine
Moderna, Inc. awarded $176 million to accelerate mRNA-based pandemic influenza vaccine development through a Consortium funded by BARDA. Collaboration aims to enhance global public health preparedness

Moderna Inc. MRNA Technology BARDA Pandemic Influenza Vaccine Global Public Health
BRIEF

published on 06/28/2024 at 13:05, 1 year 11 months ago

EMA Committee Recommends Marketing Authorization for Moderna's RSV Vaccine

Moderna MRNA Vaccine RSV EMA Marketing Authorization
PRESS RELEASE

published on 06/28/2024 at 13:00, 1 year 11 months ago

EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)
Moderna, Inc. receives positive opinion from EMA CHMP for mRESVIA mRNA-1345 vaccine for RSV in adults aged 60+. The decision from the European Commission is awaited

Moderna Inc. RSV Vaccine MRESVIA EMA CHMP MRNA-1345
BRIEF

published on 06/13/2024 at 13:05, 2 years ago

Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1283 Efficacy Data
PRESS RELEASE

published on 06/13/2024 at 13:00, 2 years ago

Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
Moderna's mRNA-1283 demonstrates non-inferior COVID-19 vaccine efficacy compared to Spikevax in Phase 3 trial. Higher efficacy in adults observed. Positive interim results reported

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1283 Spikevax
BRIEF

published on 06/10/2024 at 12:35, 2 years ago

Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1083 Influenza
PRESS RELEASE

published on 06/10/2024 at 12:30, 2 years ago

Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
Moderna's mRNA-1083 Phase 3 trial for flu and COVID combination vaccine elicits strong immune responses in adults 50+ & 65+. Promising results may reshape respiratory virus vaccination

COVID-19 Moderna Phase 3 Trial MRNA-1083 Flu
BRIEF

published on 06/07/2024 at 16:35, 2 years ago

Moderna Files FDA Application for JN.1 Targeting COVID-19 Vaccine

FDA COVID-19 Moderna Spikevax JN.1 Variant
PRESS RELEASE

published on 06/07/2024 at 16:30, 2 years ago

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
Moderna prepares to ship Spikevax 2024-2025 formula pending FDA approval for SARS-CoV-2 variant JN.1. CEO emphasizes importance of updating COVID-19 vaccines. Adverse reactions & safety info highlighted

FDA Approval COVID-19 Vaccine Moderna Spikevax 2024-2025 Adverse Reactions
BRIEF

published on 06/06/2024 at 13:05, 2 years ago

Moderna's Investigational Therapeutic for Methylmalonic Acidemia Selected by FDA for START Pilot Program

FDA Moderna MMA MRNA-3705 START Program

Accesswire

Published on 06/18/2026 at 00:00, 8 hours 10 minutes ago

LIR Life Sciences Completes Comparative Animal Study Showing Successful Protamine-Enhanced Permeation Transport of Both Semaglutide and Tirzepatide
Published on 06/17/2026 at 23:30, 8 hours 40 minutes ago

Polaris Renewable Energy Announces Postponement of Annual Meeting of Shareholders
Published on 06/17/2026 at 22:50, 9 hours 20 minutes ago

International Battery Metals Ltd. Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results
Published on 06/17/2026 at 22:30, 9 hours 40 minutes ago

Innodata Appoints Jayant Chauhan as Chief Financial Officer
Published on 06/17/2026 at 16:55, 15 hours 15 minutes ago

Snipp Interactive Named a Representative Vendor in the Gartner(R) 2026 Market Guide for Loyalty Program Vendors

View all ACCESSWIRE

EQS Group

Published on 06/18/2026 at 08:05, 5 minutes ago

Sunparl Releases First ESG Report: Showcasing ZKONG's Smart Retail Innovation and Sustainability Practices
Published on 06/18/2026 at 07:30, 40 minutes ago

tonies targets to more than double group revenue by 2030 and announces further international expansion plans at first-ever Capital Markets Day
Published on 06/18/2026 at 07:00, 1 hour 10 minutes ago

Press release: Leonteq concludes regulatory legacy matters
Published on 06/18/2026 at 07:00, 1 hour 10 minutes ago

Successful virtual Annual General Meeting: Ringmetall SE reports from Munich
Published on 06/18/2026 at 06:40, 1 hour 30 minutes ago

APES 2026: 2,000+ Chinese Source Factories, One-Stop Direct Sourcing -Maximizing Buyer Margins

Les Echos

Published on 06/18/2026 at 07:00, 1 hour 10 minutes ago

bioMérieux introduces Salmonella testing kit on GENE-UP® TYPER to support root cause analysis in the food industry
Published on 06/17/2026 at 17:40, 14 hours 30 minutes ago

Report on share repurchases from 10 to 16 June 2026
Published on 06/17/2026 at 08:45, 23 hours 25 minutes ago

Air Liquide is awarded its largest-ever contract in Spain to care for 90,000 patients living with respiratory conditions at home
Published on 06/16/2026 at 11:44, 1 day 20 hours ago

Guillemot Corporation S.A. | Weekly report share buyback from June 8 to June 12 2026
Published on 06/15/2026 at 23:00, 2 days 9 hours ago

BIOPHYTIS ANNOUNCES THE TEMPORARY SUSPENSION OF THE TRADING OF ITS SHARES

View all LES ECHOS COMFI WIRE